ESRRA and breast cancer: Furthermore, Kaplan–Meier analyses, performed on patients with any breast cancer subtype, confirmed that a poor prognosis is associated with high levels of ERRα [69,70], opening new scenarios in the treatment of breast cancer in light of the strong connection between mevalonate/cholesterol and activation of the ERRa pathway.